PHARMATREE
Pharmatree is building a research-stage biopharmaceutical development platform focused on complex protein therapeutics and proposed biosimilar candidates, including mammalian-cell culture process development and comparative characterization.
About Pharmatree
Research & Development
Pharmatree is building a research-stage biopharmaceutical development platform focused on complex protein therapeutics and proposed biosimilar candidates.
Our long-term objective is to contribute to the responsible development of complex biologic medicines through disciplined research, analytical
understanding, and continuous learning.
5 Research Programs
Research-stage proposed biosimilar candidate programs
Mammalian-Cell Platform
Mammalian-cell bioreactor process development
Comparative Analytics
Risk-based, orthogonal comparative characterization
Stage-Appropriate Process Development
Upstream, downstream & formulation
Understanding our science
Biologic medicines and biosimilars, explained in plain scientific terms.
What are biologic medicines?
A biosimilar is a biological medicine that the relevant regulatory authority has determined to be highly similar in quality characteristics to an already authorized reference biological medicine, with no clinically meaningful differences in safety and efficacy.
Understanding biosimilars
A biosimilar is a biological medicine that the relevant regulatory authority has determined to be highly similar in quality characteristics to an already authorized reference biological medicine, with no clinically meaningful differences in safety and efficacy.
Research portfolio
Research-stage proposed biosimilar candidate programs
PH1001
- Oncology
Research-stage proposed biosimilar candidate referencing trastuzumab
Directed against the extracellular domain of HER2. Target: HER2.
PH1002
- Neurology
Research-stage proposed biosimilar candidate referencing ocrelizumab
Directed against CD20-expressing B lymphocytes. Target: CD20.
PH1003
- Oncology
Research-stage proposed biosimilar candidate referencing bevacizumab
Designed to bind vascular endothelial growth factor A. Target: VEGF-A.
PH1004
- Hematology/Autoimmune
Research-stage proposed biosimilar candidate referencing rituximab
Directed against the CD20 antigen on B lymphocytes. Target: CD20.
PH1005
- Immunology
Research-stage proposed biosimilar candidate referencing infliximab
Directed against soluble and transmembrane TNF-α. Target: TNF-α.
Five programs across four therapeutic areas
A Science-Led, Risk-Based Approach
Our commitment to responsible development
All Pharmatree programs are at the research stage. Biosimilarity, safety, efficacy, approved indications, and interchangeability, where such a designation exists, have not been established for any candidate. No Pharmatree candidate has been approved by any regulatory authority.
Our capabilities
Comparative analytical characterization and stage-appropriate process development
1. Comparative Analytical Characterization
A risk-based, molecule-specific approach to evaluating how a proposed product compares with its reference product across quality attributes.
2. Upstream & Downstream Process Development
Stage-appropriate development activities spanning
mammalian-cell culture, purification, and viral-safety strategy
design.
3. Formulation Development
Stability-focused formulation development designed to
investigate and support protein quality during processing,
handling, and intended storage.